Close Menu

Scientists at Roche have used computational methods to screen for small molecule kinase inhibitors (SMKIs) that bind to more than one kinase and cause damage to chromosomes. Using a competitive binding assay, they tested the binding affinity of 113 SMKIs against a representative subset of all 290 kinases. They were able to identify kinases that correlate with chromosome damage, "providing a basis for rational drug design away from genotoxicity," they say.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.